Indian multinational company, Bharath Biotech, has submitted Covaxin’s Phase III trial
According to reliable government sources: Covid vaccine manufacturing company Bharat Biotech which is headquartered in Hyderabad submitted data from the Phase III clinical trials of Covaxin to the Drugs Controller General of India (DCGI) over the weekend.
A senior government official said, “We have received the data from the phase III trials.” 
Covaxin which is developed by Bharat Biotech is one of the major three vaccines which are currently being used in India. The phase III data of its vaccine have been questioned multiple times and that is what adds weight to the data given by the company as it will ascertain the efficacy of the vaccine.
The company has developed Covaxin in association with the Indian Council of Medical Research (ICMR).
A few days ago In a press briefing done by the Union Health Ministry, Dr V K Paul, who is a member of Niti Aayog (Health) and also the head of the Covid task force in India, said that the company would be submitting the data within eight days.
